Strong Financial Performance
Adjusted earnings per share of $2.97, $0.11 above guidance midpoint. Total net revenues were $15.4 billion, exceeding expectations by over $400 million.
Robust Growth in Key Segments
Sales growth of 22% from the ex-HUMIRA platform, with Skyrizi and Rinvoq expected to deliver more than $25 billion in combined sales this year. Neuroscience segment also showed strong double-digit growth driven by Vraylar, Vyalev, and migraine portfolio.
Increased Guidance
Full-year revenue guidance raised by $1.5 billion since the start of the year, now expecting $60.5 billion. Adjusted EPS guidance increased to between $11.88 and $12.08.
Pipeline Advancements
Notable approvals for EMRELIS in non-small cell lung cancer and Rinvoq for GCA. Regulatory submission for TrenibotE in aesthetics and positive Phase III results in alopecia areata.
Strategic Acquisitions and Collaborations
Over 30 business development transactions since last year, including acquisition of Capstan Therapeutics and collaboration with ADARx for siRNA therapies.